


"Express Mail" mailing label number EV 005609663 US

Date of Deposit: January 7, 2002

Our Case No.: 10716/35



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Mary Gerritsen et al.

Serial No.: 09/815,379

Filing Date: March 22, 2001

For: ANGIOGENESIS ASSOCIATED  
PROTEINS, AND NUCLEIC ACIDS  
ENCODING THE SAME

Examiner: To be assigned

Group Art Unit No.: 1632

#20  
10  
8212

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

FOREIGN PATENTS

DOCUMENT NUMBER	DATE	COUNTRY
WO 97/45143	12/4/97	PCT
WO 00/58473	10/5/00	PCT
WO 00/78953 A2	12/28/00	PCT
WO 01/70808 A2	9/27/01	PCT

## OTHER ART REFERENCES


Deroanne, Christophe F. et al., "Angiogenesis by Fibroblast Growth Factor 4 Is Mediated Through An Autocrine Up-Regulation of Vascular Endothelial Growth Factor Expression", <i>Cancer Research</i> , Vol. 57, 1997, pp 5590-5597.
Bloeker, H. et al., "Homo Sapiens mRNA", submitted to GenBank in Germany, 1999, Accession Number AL 117562, pp. 1-2.
Lai, C. H. et al., "Identification of Novel Human Genes Evolutionary Conserved In Caenorhabditis Elegans By Comparative Proteomics," <i>Genome Res.</i> 10 (5): 713, 2000, Accession Number AF 151831, pp. 1-2.
Ohara, O. et al., "Homo Sapiens mRNA for KIAA1489 Protein", submitted to GenBank in Japan, 2000, Accession Number AB 040922, pp. 1-2.
Nagase, T. et al., "Prediction of the Coding Sequences of Unidentified Human Genes. XVII. The Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteins <i>in vitro</i> ," <i>DNA Research</i> , Vol. 7, 2000, pp. 143-150.
Kahn, Jeanne et al., "Gene Expression Profiling in an <i>in Vitro</i> Model of Angiogenesis", <i>American Journal of Pathology</i> , Vol. 156, 2000, pp. 1887-1900.

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

Applicants respectfully request that the listed documents be made of  
record in the present case.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "G. M. Zinkl", is written over a horizontal line.

Gregory M. Zinkl Ph.D.  
Registration No. 48,492  
Agent for Applicants

BRINKS HOFER GILSON & LIONE  
P.O. Box 10395  
Chicago, IL 60610  
Tel. (312) 321-4200  
Fax (312) 321-4299

09-02


GP1632

RECEIVED

JAN 15 2002

TECH CENTER 1600/2905

TRANSMITTAL LETTER			Case No. 10716/35
Serial No. 09/815,379	Filing Date March 22, 2001	Examiner To be assigned	Group Art Unit 1632
Inventor(s) Mary Gerritsen et al.			
Title of Invention CANGIOGENESIS ASSOCIATED PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME			



TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an Information Disclosure Statement; Form PTO-1449; copy of cited references A1- and return post card.

- ☐ Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.
- ☐ Petition for a \_\_\_\_\_ month extension of time.
- ☒ No additional fee is required.
- ☐ The fee has been calculated as shown below:

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra
Total		Minus		
Indep.		Minus		
First Presentation of Multiple Dep. Claim				

Small Entity		or	Other Than Small Entity	
Rate	Add'l Fee		Rate	Add'l Fee
x \$9=			x \$18=	
x 42=			x \$84=	
+\$140=			+\$280=	
Total add'l fee	\$		Total add'l fee	\$

- ☐ Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$\_\_\_\_\_. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$\_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.
- ☒ I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

\_\_\_\_\_  
Gregory M. Zinkl, Ph.D.  
Registration No. 48,492  
Agent for Applicants

BRINKS HOFER GILSON & LIONE  
P.O. BOX 10395  
CHICAGO, ILLINOIS 60610  
(312) 321-4200

I hereby certify that this correspondence is being deposited in Express Mail Label No. EV 005609663 US envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on January 7, 2002.

Date: 01/07/02 Signature: